This CPB is revised to state that bortezomib is considered medically necessary for progressive solitary plasmacytoma. This policy revision is based upon guidelines from the National Comprehensive Cancer Network. This CPB has been revised to state that bortezomib is considered experimental and investigational for the treatment of ovarian cancer and Waldenstrom's macroglobulinemia.